Project Details
Description
Project Abstract
Tuberculosis (TB) continues to be a major global health problem with 9 million new
cases per year resulting in 1.7 million deaths, due in large part to the HIV epidemic and
emergence of multi- and extensively drug resistant TB strains (MDR- and XDR-TB) that
have confounded TB control. There will be no lasting reduction of TB morbidity and
mortality without rapid and cost-effective TB diagnostics, efficacious vaccines, and
shortened, well-tolerated chemotherapy, which can only be developed on the foundation
of understanding the biology of the tubercle bacilli and subsequent host-pathogen
interactions. The goal of this proposal is to accelerate TB research through the
completion and distribution of 4,000 specialized transducing reagents to make precise
null bar-coded deletion (PNBCD) mutants in every gene of M. tuberculosis. We plan to
make mutants in virulent Mtb strains and mc27902, an attenuated Mtb strain that can be
used under BSL2-containment. We will partner with ATCC (BEI) for distribution of these
and distribution
Status | Active |
---|---|
Effective start/end date | 9/14/17 → 6/30/24 |
Funding
- National Institute of Allergy and Infectious Diseases: $428,706.00
- National Institute of Allergy and Infectious Diseases: $764,494.00
- National Institute of Allergy and Infectious Diseases: $572,071.00
- National Institute of Allergy and Infectious Diseases: $572,071.00
- National Institute of Allergy and Infectious Diseases: $572,071.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.